3B Blackbio DX Ltd Q1 FY27 results (latest), Apr–Jun 2026 →See revenue, profit and what management said. You are viewing Q4 FY24.
3B

3B Blackbio DX Ltd

Q4 FY24Healthcare Services

3B Blackbio DX Q4 FY24 earnings call: Revenue & Margins

Q4 FY24 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹23Cr
+27.8% YoY
+27.8% QoQ
Net profit
₹9Cr
+80% YoY
0% QoQ
Margin
43%
+2 pp YoY
−7 pp QoQ

Based on 3B Blackbio DX Ltd's Q4 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹1,406
Market cap₹1.1K Cr
P/E20.4

The short version

Q4 FY 2023-24 total revenue: INR 2,719.24 lakh vs. Quarterly EBITDA: INR 1,372.90 Lakh in Q4 FY 2023-24 vs.

From 3B Blackbio DX Ltd's Q4 FY24 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q4 FY 2023-24 total revenue: INR 2,719.24 lakh vs. INR 1,926.42 lakh in Q4 FY 2022-23 (approx. 41% increase).
  • Q4 FY 2023-24 molecular diagnostic kits export sales: INR 290.15 lakh vs. INR 188.33 lakh in Q4 FY 2022-23 (~54% increase).
  • Effective growth in Non-COVID Sales for Q4 FY 2023-24 approx. 20%, in line with expectations.
  • Diagnostics business (3B Standalone Non-COVID) Q4 Sales: INR 1,721.40 lakh vs. INR 1,433.41 lakh in Q4 FY 2022-23 (~20% growth).
  • Export business (non-COVID) increased by over 25% from previous fiscal, projecting 20-25% growth for next year.
  • TRUPCR Europe Limited, Manchester site expected 40-50% growth next fiscal year.

2 more points from 3B Blackbio DX Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company is continuously investing in additional manufacturing and R&D facilities to support existing business verticals (Page 34).
  • Expansion efforts include enhancing operations at the UK subsidiary, TRUPCR® Europe Limited in Manchester, with a projected growth rate of 40%-50% next fiscal year (Page 24).
  • Funds will be deployed in a joint venture in Manchester, UK, dependent on need (Page 34).
  • The company is exploring acquisitions for inorganic growth since FY22 but will proceed only if financially sensible; if not, a share buyback is planned (Page 34).

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

It focuses on: - Long-term contracts (Page 33) with over 20 contracts under a Reagent-Rental Model providing stable revenue, projecting 15%-20% business from these contracts. - Sales growth and export business expansion (Pages 16, 19) indicating increasing demand but without specific order inflow or pending orders data. - Business outlook, capacity expansion, and strategic initiatives aimed at growth and market penetration (Pages 14, 34).

3B Blackbio DX Ltd — Quarterly revenue & net profit

Revenue Net profit
Sep 2024Q2 FY25
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26

3B Blackbio DX Ltd Q4 FY24 results — key figures

3B Blackbio DX Ltd Q4 FY24 reported results vs Q4 FY23, ₹ crore
₹ CrQ4 FY24Q4 FY23YoYQ3 FY24QoQ
Revenue2318+27.8%18+27.8%
Operating profit (EBITDA)107+42.9%9+11.1%
Operating margin43%41%+2 pp50%-7 pp
Profit before tax148+75%11+27.3%
Net profit (PAT)95+80%90%
EPS (₹)10.337.72+33.8%10.16+1.7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were 3B Blackbio DX Ltd Q4 FY24 results?

Q4 FY 2023-24 total revenue: INR 2,719.24 lakh vs. Quarterly EBITDA: INR 1,372.90 Lakh in Q4 FY 2023-24 vs.

What is 3B Blackbio DX Ltd share price analysis?

3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.

Is 3B Blackbio DX Ltd planning capital expenditure?

The company is continuously investing in additional manufacturing and R&D facilities to support existing business verticals (Page 34).

Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.